Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

Blood

Volumn 113, Issue 20, 2009, Pages 4875-4884

  Gertner Dardenne, Julie ^a,b,c   Bonnafous, Cecile ^d   Bezombes, Christine ^a,b   Capietto, Aude Hélène ^a,b   Scaglione, Virginie ^d   Ingoure, Sophie ^d   Cendron, Delphine ^a,b   Gross, Emilie ^a,b   Lepage, Jean François ^d   Quillet Mary, Anne ^a,b   Ysebaert, Loîc ^a,b   Laurent, Guy ^a,b   Sicard, Hélène ^d   Fournié, Jean Jacques ^a,b  

^a CHU PURPAN   (France)

^b France   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d INNATE PHARMA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY; ANTIGEN; BROMOHYDRIN PYROPHOSPHATE; CD20 ANTIBODY; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOANTIGEN; PROTEIN KINASE ZAP 70; PYROPHOSPHATE; RITUXIMAB; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA 9; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PHOSPHATE; TCRVGAMMA9 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL ACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LYMPH NODE; LYMPHOMA CELL; MACACA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ADULT; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLOOD; CELL CULTURE; CHEMISTRY; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECT; DRUG SCREENING; FEMALE; IMMUNOLOGY; MALE; METABOLISM; T LYMPHOCYTE; UPREGULATION;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CELLS, CULTURED; DIPHOSPHATES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INTERLEUKIN-2; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MACACA FASCICULARIS; MALE; PHOSPHATES; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; UP-REGULATION;

EID: 66549084068     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-172296     Document Type: Article

References (50)

1. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343-357.
2. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34-47.
3. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-446. (Pubitemid 30208162)
4. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758. (Pubitemid 34525533)
5. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-3947. (Pubitemid 46606207)
6. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733-26740 (Pubitemid 34951677)
7. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103:4005-4010.
8. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26:1789-1796.
9. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635-2642. (Pubitemid 39434941)
10. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7:329-339. (Pubitemid 46674487)
11. Espinosa E, Belmant C, Pont F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem. 2001;276:18337-18344 (Pubitemid 37411407)
12. Bonneville M, Fournie JJ. Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect. 2005;7:503-509. (Pubitemid 40603450)
13. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007;67:5-8. (Pubitemid 46142752)
14. Casetti R, Perretta G, Taglioni A, et al. Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2. J Immunol. 2005;175:1593-1598. (Pubitemid 41023061)
15. Sicard H, Ingoure S, Luciani B, et al. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol. 2005;175:5471-5480.
16. Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T. Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol Immunother. 2001;50:115-124. (Pubitemid 32480555)
17. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102:200-206. (Pubitemid 36759655)
18. Dieli F, Gebbia N, Poccia F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003;102:2310-2311. (Pubitemid 37122416)
19. Viey E, Fromont G, Escudier B, et al. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol. 2005;174:1338-1347.
20. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67:7450-7457. (Pubitemid 47206575)
21. Bennouna J, Medioni J, Rolland F, et al. Phase I clinical trial of bromohydrin pyrophosphate BrHPP (phosphostim) a Vg9Vd2 T lymphocytes agonistin combination with low-dose interleukin-2 in patients with solid tumors [Abstract 2536]. J Clin Oncol. 2005;23:174S.
22. Bennouna J, Bompas E, Neidhardt EM, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2008;57:1599-1609.
23. Lafont V, Liautard J, Liautard JP, Favero J. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen. J Immunol. 2001;166:7190-7199. (Pubitemid 32525592)
24. Dieli F, Poccia F, Lipp M, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med. 2003;198:391-397. (Pubitemid 36980610)
25. Angelini DF, Borsellino G, Poupot M, et al. Fc-gammaRIII discriminates between two subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood. 2004;104:1801-1807. (Pubitemid 39202290)
26. Poupot M, Pont F, Fournie JJ. Profiling blood lymphocyte interactions with cancer cells uncovers the innate reactivity of human gamma delta T cells to anaplastic large cell lymphoma. J Immunol. 2005;174:1717-1722.
27. Tokuyama H, Hagi T, Mattarollo SR, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs: rituximab and trastuzumab. Int J Cancer. 2008;122:2526-2534. (Pubitemid 351590486)
28. Gertner J, Wiedemann A, Poupot M, Fournie JJ. Human gammadelta T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett. 2007;110:42-53. (Pubitemid 46678226)
29. Leseux L, Laurent G, Laurent C, et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood. 2008;111:285-291.
30. Gertner-Dardenne J, Poupot M, Gray B, Fournie JJ. Lipophilic fluorochrome trackers of membrane transfers between immune cells. Immunol Invest. 2007;36:665-685.
31. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445. (Pubitemid 24030569)
32. Cragg MS, Bayne MB, Tutt AL, et al. A new antiidiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood. 2004;104:2540-2542.
33. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science. 2004;306:1517-1519. (Pubitemid 39564941)
34. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human Vgamma9Vdelta2 gammadelta T cells in vitro and in SCID mice in vivo. J Immunol. 2004;173:6767-6776. (Pubitemid 39541063)
35. Tabiasco J, Espinosa E, Hudrisier D, Joly E, Fournie JJ, Vercellone A. Active trans-synaptic capture of membrane fragments by natural killer cells. Eur J Immunol. 2002;32:1502-1508. (Pubitemid 34546279)
36. Espinosa E, Tabiasco J, Hudrisier D, Fournie JJ. Synaptic transfer by human gamma delta T cells stimulated with soluble or cellular antigens. J Immunol. 2002;168:6336-6343. (Pubitemid 34620056)
37. Fisch P, Meuer E, Pende D, et al. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity. Eur J Immunol. 1997;27:3368-3379. (Pubitemid 28018034)
38. Guilloton F, Jean C, de Thonel A, Laurent G, Quillet-Mary A. Granzyme B induction signalling pathway in acute myeloid leukemia cell lines stimulated by tumor necrosis factor alpha and Fas ligand. Cell Signal. 2007;19:1132-1140. (Pubitemid 46561551)
39. Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol. 2003;30:483-492. (Pubitemid 36999690)
40. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;188:2427-2437.
41. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12:19-28. (Pubitemid 37321502)
42. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117:1137-1146.
43. Bhardwaj N. Harnessing the immune system to treat cancer. J Clin Invest. 2007;117:1130-1136. (Pubitemid 46718397)
44. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109:405-411.
45. Robak T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat Rev. 2007;33:710-728. (Pubitemid 350089291)
46. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97:256-263. (Pubitemid 32061268)
47. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106:2018-2025. (Pubitemid 41291715)
48. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gamma-delta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163-168. (Pubitemid 36152311)
49. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res. 2004;19:278-288. (Pubitemid 38116742)
50. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603-3613.